4//SEC Filing
Tammenoms Bakker Juliet 4
Accession 0000950170-23-047537
CIK 0001111485other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 6:15 PM ET
Size
13.4 KB
Accession
0000950170-23-047537
Insider Transaction Report
Form 4
RxSight, Inc.RXST
Tammenoms Bakker Juliet
Director
Transactions
- Sale
Common Stock
2023-09-08$30.25/sh−10,033$303,461→ 23,173 total - Sale
Common Stock
2023-09-07$30.10/sh−19,967$600,983→ 33,206 total - Sale
Common Stock
2023-09-11$30.01/sh−2,950$88,525→ 20,223 total
Holdings
- 994,313(indirect: See footnote)
Common Stock
- 855(indirect: See footnote)
Common Stock
- 445,400(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 1 to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
- [F4]These securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting, investment and dispositive power with respect to such securities. The Reporting Person, a member of the Issuer's board of directors, and Patrick G. Enright are the managing members of LCP II and may be deemed to share voting, investment and dispositive power over such securities. Each of LVP II, LCP II, Mr. Enright and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- [F5]The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting, investment and dispositive power with respect to such securities. The Reporting Person, a member of the Issuer's board of directors, and Mr. Enright are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPF, LPP, Mr. Enright and the Reporting Person disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- [F6]These securities are held by a trust. The Reporting Person, a member of the Issuer's board of directors, is the Investment Trustee of such trust and may be deemed to share voting, investment and dispositive power with respect to such securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
RxSight, Inc.
CIK 0001111485
Entity typeother
Related Parties
1- filerCIK 0001431159
Filing Metadata
- Form type
- 4
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 6:15 PM ET
- Size
- 13.4 KB